Targeting the IL-6/IL-17 amplifier loop in fibroblasts: insights from chronic antibody-mediated rejection in kidney transplant patients
The Journal of Immunology · 15.04.2026 · 215 (4)
DOI: 10.1093/jimmun/vkag057 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 26.04.2026. Verfasst von Mantabya Kumar Singh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India. Hauptthemen laut MEDLINE: Interleukin-6, Fibroblasts, Kidney Transplantation, Interleukin-17. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Sanjay Gandhi Postgraduate Institute of Medical Sciences.
Abstract (Originalsprache)
Chronic antibody-mediated kidney rejection (CABMR) is a major cause of chronic allograft injury. Fibroblasts have been implicated in mediating this injury through activation of the IL-6 amplifier loop (IL-6 + IL-17), driven by the NF-κB and STAT3 signaling pathways. This study investigated the activation of the IL-6 amplifier loop in fibroblasts isolated from renal biopsies of patients with CABMR and evaluated the effects of IL-6 and IL-17 inhibition. Fibroblasts were cultured from 6 CABMR patient biopsy samples and treated with anti-IL-6 (100 ng/mL) and anti-IL-17 (0.75 µg/mL), both before and after stimulation with IL-6/soluble IL-6 receptor (sIL-6R) (20 ng/µL), IL-17 (50 ng/µL), or a combination. IL-6, CCL2, and CCL20 levels were measured in the culture supernatants by ELISA. The mRNA expression of IL-6, CCL2, CCL20, and SOCS3 was assessed using qPCR, and protein expression was evaluated by western blot for phosphorylated STAT3 and NF-κB p65. Synergistic activation of IL-6/sIL-6R and IL-17 significantly increased IL-6, CCL20, and MCP-1 production, whereas SOCS3 expression was downregulated. Phosphorylation of NF-κB and STAT3 was also elevated. The combined inhibition of IL-6 and IL-17 effectively reduced IL-6, MCP-1, and CCL20 levels, restored SOCS3 expression, and attenuated NF-κB and STAT3 phosphorylation. These findings highlight the role of the IL-6 amplifier loop as a potential therapeutic target in CABMR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
- Clinical Immunology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
ORCID-Profile: Vikas Agarwal, Narayan Prasad
Förderung
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Zitieren
APA
Singh, M. K., Rai, M. K., Singh, H., Agarwal, V., & Prasad, N. (2026). Targeting the IL-6/IL-17 amplifier loop in fibroblasts: insights from chronic antibody-mediated rejection in kidney transplant patients. The Journal of Immunology, 215(4). https://doi.org/10.1093/jimmun/vkag057
Vancouver
Singh MK, Rai MK, Singh H, Agarwal V, Prasad N. Targeting the IL-6/IL-17 amplifier loop in fibroblasts: insights from chronic antibody-mediated rejection in kidney transplant patients. The Journal of Immunology. 2026;215(4). doi:10.1093/jimmun/vkag057
BibTeX
@article{Singh2026,
author = {Singh, Mantabya Kumar and Rai, Mohit Kumar and Singh, Harshit and Agarwal, Vikas and Prasad, Narayan},
title = {Targeting the IL-6/IL-17 amplifier loop in fibroblasts: insights from chronic antibody-mediated rejection in kidney transplant patients},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {4},
doi = {10.1093/jimmun/vkag057}
}
EUVIMED